文献速递糖尿病

IGFBP7预测2型糖尿病患者的肾脏和心血管结局

Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study.
PubMed 文献 · Diabetes Care · 2020-11-06

在CANVAS试验中,基线血浆IGFBP7水平与2型糖尿病高心血管风险患者的复合肾脏终点及肾脏终点加心血管死亡显著相关。坎格列净的获益在基线IGFBP7≥96.5 ng/mL者中对于白蛋白尿进展更明显,且1年时较高IGFBP7更强预测肾脏终点。

要点

  • 基线IGFBP7每升高一个对数单位,复合肾脏终点风险HR 3.51,加心血管死亡HR 4.90。
  • 基线IGFBP7≥96.5 ng/mL者使用坎格列净对白蛋白尿进展获益更显著(HR 0.64 vs 0.95)。
  • 坎格列净未降低1年IGFBP7水平,但1年时较高IGFBP7更强预测肾脏终点(HR 15.7)。

核心结论

  • 血浆IGFBP7浓度可预测2型糖尿病高心血管风险患者的肾脏和心脏事件。

研究设计与样本

  • CANVAS试验的事后分析,纳入2型糖尿病高心血管风险参与者,基线3577例和1年2898例有IGFBP7测量。

主要发现

  • 基线IGFBP7每升高一个对数单位,复合肾脏终点HR 3.51(P<0.001),复合肾脏终点加心血管死亡HR 4.90(P<0.001)。
  • 基线IGFBP7还预测白蛋白尿发生或进展等其他结局。
  • 坎格列净对多数结局的改善与基线IGFBP7无关,但基线≥96.5 ng/mL者白蛋白尿进展获益更明显(HR 0.64 vs 0.95,P交互=0.003)。
  • 坎格列净未降低1年IGFBP7浓度,但1年时较高IGFBP7更强预测复合肾脏终点(HR 15.7,P<0.001)。
  • 基线至1年IGFBP7升高的患者复合肾脏事件数最高。

临床怎么用

  • IGFBP7可作为2型糖尿病高心血管风险患者肾脏和心血管事件的预测标志物。
  • 基线IGFBP7≥96.5 ng/mL可能提示坎格列净对白蛋白尿进展的获益更大。

局限性

  • 需要更多关于循环IGFBP7与糖尿病肾病进展及其并发症的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze the association between concentrations of plasma insulin-like growth factor binding protein 7 (IGFBP7) with renal and cardiac outcomes among participants with type 2 diabetes and high cardiovascular risk. RESEARCH DESIGN AND METHODS: Associations between IGFBP7 levels and clinical outcomes were assessed among participants in the Canagliflozin Cardiovascular Assessment Study (CANVAS) with type 2 diabetes and high cardiovascular risk. RESULTS: Among CANVAS participants, 3,577 and 2,898 had IGFBP7 measured at baseline and 1 year, respectively. Per log-unit higher concentration, baseline IGFBP7 was significantly associated with the composite renal end point of sustained 40% reduction in estimated glomerular filtration rate, need for renal replacement therapy, or renal death (hazard ratio [HR] 3.51; P < 0.001) and the composite renal end point plus cardiovascular death (HR 4.90; P < 0.001). Other outcomes, including development or progression of albuminuria, were also predicted by baseline IGFBP7. Most outcomes were improved by canagliflozin regardless of baseline IGFBP7; however, those with baseline concentrations ≥96.5 ng/mL appeared to benefit more from canagliflozin relative to the first progression of albuminuria compared with those with lower baseline IGFBP7 (HR 0.64 vs. 0.95; P interaction = 0.003). Canagliflozin did not lower IGFBP7 concentrations by 1 year; however, at 1 year, higher IGFBP7 concentrations more strongly predicted the composite renal end point (HR 15.7; P < 0.001). Patients with rising IGFBP7 between baseline and 1 year had the highest number of composite renal events. CONCLUSIONS: Plasma IGFBP7 concentrations predicted renal and cardiac events among participants with type 2 diabetes and high cardiovascular risk. More data are needed regarding circulating IGFBP7 and progression of diabetic kidney disease and its complications.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Januzzi JL, Butler J, Sattar N, et al. Insulin-Like Growth Factor Binding Protein 7 Predicts Renal and Cardiovascular Outcomes in the Canagliflozin Cardiovascular Assessment Study. Diabetes Care. 2020. PMID: 33158949. doi:10.2337/dc20-1889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。